INO trade ideas
INO Rounding w/RetestINO has retested the 19 level and held that support level w/remount back over the moving averages. This is a bullish move. INO is also forming a rounding formation. These are indicators of price to go back to the $32 level.
INO: only going upLooking at the trends and the candle sticks, I think INO is going up for the coming weeks/months. However, all very much depending on the outcome of the ongoing clinical trial: some results leaked and these were moderately positive (clinicaltrials.gov and www.pharmaceutical-technology.com). If the final results are disappointing or negative, it will go down, fast. Otherwise it will get a boost and easily reach over $30 towards $40. In the mean time I expect it to swing around $22-$24.
Wondering what you think?
Disclaimer: am a newbie, so also here to learn. Happy to receive constructive feedback.
Upward TrajectoryAll it will take is a little positive news to sent $INO to new 52 week highs. Lots of news potential in July. Support in low 20s confirmed. MACD about to go green, trend is up. Establish call option position here and add on the way up.
INO may of found its bottom.As you can see from the simple chart below. INO appears to be back on its path of growth it was on before it went Parabolic on the news that the DoD was buying $70m worth of Inovio vaccine injectors. They are submitting their Phase I trial data to peer reviewed journals (as it always does) on Monday. None of the other vaccine candidates in Operation Warp Speed have peer reviewed studies on any of their CVOID19 candidates.
This in combination with being accepted into Operation Warp Speed almost guarantees funding will be coming from Barda or CEPI as every other candidate in OWS has received. What you are seeing here is the MM manipulation knocking out scared retail to buy up the stock. For some context you can see MRNA chart behaved in a near exact way. Peeking at 31 a share on good news of a mouse study before the sell of to ~$18 and then slow steady climb to a ATH $91. INO also behaved in a similar fashion last month on pre-clicincal study where it rocketed the stock to $20 before it sold of back down to $13. This is classic Biotech market behavior.
$INO Turns Sour After Parabolic Squeeze Meets Opaque UpdateINO has been one of the real poster-boys for the so-called Robinhood bubble.
The company is a chronic underperformer in the biotech space with a likely failed vaccine candidate -- given its lack of detail in any update -- powering the action despite the fact that vaccines generally aren't profitable in the first place, and this isn't going to be it. Caution!
$INO Inovio Overbought - RSI Trending Down$INO Inovio Overbought RSI Trending Down
High risk short play, but will likely see a retrace back to March high just under $20.00 in near term.
Note: Not investment advice.
INO Clouds UPInovio races for the COVID19 Vaccine. Buy now and aim for the clouds (≥$35 shortly). The indicators here are preparing for a breakout. E.g. the Ichimoku #2 (link below) indicates a momentum change when price enters its range.
docs.google.com
Inovio Trade 29/06/20Inovio NASDAQ:INO performed incredibly well last week due do a $71 grant from the DoD and pending Phase 1 results of INO-4800 which were said to be realeased late June.
Expect a dip, before rising to analysts target of $45.
Fundemental Analysis
1. Dr Fauci announced yesterday evening that positive vaccine results were to be released over the next few days.
2. China and South Korea implementation of Phase 1 which will be funded by CEPI.
3. S. Korea, BARDA and DARPA funding to come.
4. Likely approval from FDA to go onto phase 3 trials when results are confirmed to be positive.
Technical Analysis
1. Volume picking up massively this last week, as RobinHood traders continue to get on board.
2. RSI fallen towards 50 after Fridays slight fall in stock price, giving the stock a chance for another sudden rise in prices.
3. Strong support levels around 27.55 and 23.51
INO Puts/ShortsBlue line is price action target where I would enter shorts. TTM squeeze slowing down heavily, MACD nearing a short position. If you decide to enter this remeber this is a high risk high reward put, you can always eat expiration date farther out just in case we have some more momentum. However, I firmly believe this will have a correction. 💵 Play it smart🚨
Short INOLooking way over bought. Target between the 15-20 range.
Slight bounce at 24 before going lower.
Stop at 31.5.
Best of Luck,
--d0x
INO BACK TO $16-18yo yo
alright so it broke out the past two days because they received funding for COVID testing. So the rally happened and if you got in that's awesome. The RSI indicates that it is overbought. My expectation is that it sells tomorrow (June 25) and goes back down to around 16-18. If it hits 15$ and bounces back up then that's a good indication that it should come back up! Don't buy yet. it is at the top. second support is 11$
anything can happen so just keep an eye on it !
good luck
trade smart.
:)
Inovio gets $71 million from U.S. defense dept for COVID-19INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
- U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine
- INOVIO to report on interim U.S. Phase 1 clinical trial results in late June
- INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer
finance.yahoo.com
Inovio gets $71 million from U.S. defense dept for COVID-19 vaccine device
Inovio Pharmaceuticals Inc said on Tuesday it has received $71 million from the U.S. Department of Defense (DoD) to scale up production of the company's devices that are used to administer its experimental COVID-19 vaccine into the skin.
Inovio, which began human testing of its vaccine in April, said it expects to report interim results from the trial later this month, and added that it would begin mid-stage trials this summer.
There are currently no approved vaccines for COVID-19, the disease caused by the novel coronavirus, with governments, drugmakers and researchers working on about 100 vaccine programs.
finance.yahoo.com
It also said as part of this agreement that the DoD plans to buy an undisclosed number of the devices.
The vaccine candidate is currently being tested in a Phase 1 clinical trial; interim results from that study are expected to be released this month.
www.marketwatch.com
The U.S. Food and Drug Administration cleared the vaccine for testing in April.
INO-4800 targets the major surface antigen protein that causes covid-19. And the Phase I trial showed that vaccination generated robust binding and neutralizing antibody as well as T-cell responses in animals.
Phase I clinical studies of the vaccine will be available next month and a Phase II/III efficacy trial is planned for July or August, the company said.
www.thestreet.com
realmoney.thestreet.com
$INO IdeaWatched at $20 and it went up to $21.28 and beyond. Thanks to a friend, keeping me posted, it was a good look if they got in at the $20....
I believe its going to be shorted like $UONE for a good day then rally back up so, Imma keep a eye on this pull back.
Maybe to 19 or 20 dollars?
INOVIO Receives $71 Million Contract From U.S. Department of DefINO: INOVIO Pharmaceuticals, Inc.
2020-06-23 07:30:00
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine
